article thumbnail

Abiraterone acetate by Tavanta Therapeutics for Hormone-Sensitive Prostate Cancer: Likelihood of Approval

Pharmaceutical Technology

Abiraterone acetate is under clinical development by Tavanta Therapeutics and currently in Phase III for Hormone-Sensitive Prostate Cancer.

Hormones 130
article thumbnail

First European Hormone Day underscores the importance of hormones

Scienmag

Hormones are crucial to prevent, treat, and manage many of the world’s most common diseases. The role of hormonal health and disease in European Health Policies has so far been insufficiently recognized. This is why The European Society of Endocrinology (ESE), together with the European Hormone […].

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Managing menopause: Hormone therapy is back

Medical Xpress

A new review published in the Canadian Medical Association Journal (CMAJ ) recommends menopausal hormone therapy, historically known as hormone replacement therapy (HRT), as first-line treatment in people without risk factors.

article thumbnail

Ibutamoren mesylate by Lumos Pharma for Growth Hormone Deficiency: Likelihood of Approval

Pharmaceutical Technology

Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase II for Growth Hormone Deficiency. According to GlobalData, Phase II drugs for Growth Hormone Deficiency have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. It is administered orally.

Hormones 100
article thumbnail

New male contraceptive does not involve hormones

Medical Xpress

Instead of using hormones to disrupt sperm production, the new technique involves placing a hydrogel called ADAM into the vas deferens to prevent sperm from making its way to the urethra. A team of researchers at a company called Contraline has developed a new kind of male contraceptive.

Hormones 143
article thumbnail

All hormonal contraceptives increase breast cancer risk: Study

Medical Xpress

All hormonal contraceptives carry a slightly increased risk of breast cancer, including the increasingly popular progestogen-only pills, according to a study published on Tuesday.

article thumbnail

Pfizer, OPKO Get FDA Nod for Pediatric Growth Hormone Deficiency Drug

BioSpace

Overcoming an FDA rejection in January 2022, Pfizer and OPKO’s Ngenla will provide a long-acting, reduced-frequency treatment option for children with growth hormone deficiency.